Patents by Inventor Lisa Coles

Lisa Coles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING PRADER-WILLI SYNDROME
    Publication number: 20240415806
    Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).
    Type: Application
    Filed: March 18, 2024
    Publication date: December 19, 2024
    Inventors: Lisa Cole BURNETT, Dieter EGLI, Rudolph L. LEIBEL, Sara COTTER
  • Methods of treating Prader-Willi syndrome
    Patent number: 11957656
    Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: April 16, 2024
    Assignees: The Trustees of Columbia University in the City of New York, Levo Therapeutics, Inc.
    Inventors: Lisa Cole Burnett, Dieter Egli, Rudolph L Leibel, Sara Cotter
  • SYNERGISTIC IMMUNOSTIMULATION THROUGH THE DUAL ACTIVATION OF TLR3/9 WITH SPHERICAL NUCLEIC ACIDS
    Publication number: 20220370490
    Abstract: The present disclosure is generally directed to spherical nucleic acids (SNAs) comprising multiple TLR agonists that enable the simultaneous activation of multiple TLR pathways for maximally synergistic immune activation. In some aspects, the present disclosure provides a spherical nucleic acid (SNA) comprising: (a) a nanoparticle core; (b) one or more toll-like receptor 3 (TLR3) agonists encapsulated in the nanoparticle core; and (c) a shell of oligonucleotides attached to the external surface of the nanoparticle core, the shell of oligonucleotides comprising one or more toll-like receptor 9 (TLR9) agonist oligonucleotides. Methods of using the SNAs are also provided herein.
    Type: Application
    Filed: May 20, 2022
    Publication date: November 24, 2022
    Inventors: Chad A. Mirkin, Ziyin Huang, Lisa Cole, Cassandra Elizabeth Callmann, Shuya Wang
  • METHOD OF DELIVERY OF INTRAVENOUS BACLOFEN
    Publication number: 20220202753
    Abstract: Methods for the intravenous (IV) administration of a therapeutically effective amount of baclofen at a dosing regimen which mimics the oral pharmacokinetic profile of baclofen are disclosed. The disclosed methods meet bioequivalence criteria for both systemic exposure (AUC) and maximum plasma concentration (Cmax) compared to oral administration.
    Type: Application
    Filed: December 17, 2021
    Publication date: June 30, 2022
    Inventors: Prasad Tata, Dan Simon Alhadeff, Adolfo L. Gomez, John Schrogie, Robert L Kriel, Linda Krach, James C. Cloyd, Gilberto Diaz, Lisa Coles, Natalie Schmitz
  • METHODS OF TREATING PRADER-WILLI SYNDROME
    Publication number: 20210113521
    Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).
    Type: Application
    Filed: October 26, 2020
    Publication date: April 22, 2021
    Inventors: Lisa Cole BURNETT, Dieter EGLI, Rudolph L. LEIBEL, Sara COTTER
  • Methods of treating Prader-Willi syndrome
    Patent number: 10842775
    Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: November 24, 2020
    Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, LEVO THERAPEUTICS, INC.
    Inventors: Lisa Cole Burnett, Dieter Egli, Rudolph L. Leibel, Sara Cotter
  • METHODS OF TREATING PRADER-WILLI SYNDROME
    Publication number: 20190298686
    Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).
    Type: Application
    Filed: June 2, 2017
    Publication date: October 3, 2019
    Applicants: The Trustees of Columbia University in the City of New York, Levo Therapeutics, Incs, Inc.
    Inventors: Lisa Cole BURNETT, Dieter EGLI, Rudolph L. LEIBEL, Sara COTTER